Moderna’s historic cancer-vaccine breakthrough has transformed the investment case around the biotech company, but one Wall Street firm now says investors have pushed the stock too far ahead of the evidence.
Rothschild & Co Redburn analyst Simon Baker downgraded Moderna to Sell from Neutral on Thursday while raising his price target to $81 from $40. The unusual combination reflects a more optimistic assessment of Moderna’s cancer program than before, but a much more cautious view of what is already embedded in the stock price.
The new target represents roughly 46% downside from Moderna’s September 2 closing price of $150.81.
Shares opened Thursday at $145.95 and briefly fell to $142.78 before recovering much of the decline. Moderna finished the session at $148.87, down 1.3%, even as the broader market rallied.
The downgrade comes after one of the most dramatic biotech rallies in years. Moderna shares surged 156% during August, making the company the best-performing stock in the S&P 500 for the month. On August 19 alone, the stock jumped from roughly $63 to more than $174 after Moderna and Merck announced positive Phase 3 results for their experimental personalized cancer treatment intismeran autogene.
Baker described the melanoma result as a major scientific success. His concern is what investors are assuming comes next.
Rothschild said the stock’s valuation appears to assume something close to widespread use of intismeran across numerous cancers despite limited clinical evidence outside melanoma. The firm said the market reaction implies broad adoption “across tumor types for which we have seen little or no data.”
That puts Moderna investors at the center of a difficult valuation question: how much should a company be worth after proving its technology works in one major cancer setting when much of the long-term opportunity still depends on trials that have not yet produced definitive results?
The Phase 3 Melanoma Result Was a Genuine Breakthrough
The enthusiasm behind Moderna’s rally was not based simply on speculation.
On August 19, Moderna and Merck announced that the Phase 3 INTerpath-001 study of intismeran autogene combined with Merck’s Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint measuring distant metastasis-free survival.
The study evaluated more than 1,000 patients whose high-risk stage IIB through IV melanoma had been completely removed surgically.
The combination produced statistically significant and clinically meaningful improvements compared with Keytruda alone, according to the companies, with no new safety signals identified.
It became the first positive Phase 3 readout for an individualized neoantigen therapy and the first successful Phase 3 study of an mRNA-based cancer treatment. It was also the first Phase 3 trial in this setting to demonstrate a clinically meaningful improvement over Keytruda alone.
Those are substantial milestones for Moderna.
The company’s reputation and financial success were built around COVID-19 vaccines, but investors have spent years questioning whether its mRNA platform could produce another commercially transformative franchise.
Intismeran provides the strongest evidence yet that it can.
The therapy is customized for each patient. Tumor samples are analyzed to identify mutations unique to that person’s cancer, and an individualized mRNA treatment is then created to train the immune system to recognize those tumor-specific targets.
Merck’s Keytruda helps remove mechanisms cancer cells use to evade the immune system.
The combination therefore attacks the problem from two directions: identifying the cancer’s unique mutations while helping the immune system respond to them.
Detailed Phase 3 Data Still Matter
There is also an important limitation to the August announcement.
Moderna and Merck have not yet publicly released the full numerical Phase 3 results.
The companies confirmed that recurrence-free survival and distant metastasis-free survival improved significantly, but investors do not yet have the full hazard ratios, survival curves and subgroup analyses needed to judge the magnitude of the benefit.
Overall survival is also still being evaluated.
That makes the upcoming medical presentation one of Moderna’s most important catalysts. The complete dataset will allow oncologists, regulators and investors to judge whether the Phase 3 benefit is merely statistically successful or strong enough to support widespread commercial adoption.
Earlier-stage data provide a promising benchmark.
At five years of follow-up in the previous Phase 2b study, intismeran plus Keytruda reduced the risk of melanoma recurrence or death by 49% compared with Keytruda alone. It also reduced the risk of distant metastasis or death by 59%.
An exploratory analysis showed a favorable overall-survival trend, although the number of deaths remained too small to draw a definitive conclusion.
Those results held up over five years, strengthening confidence that the benefit was durable rather than temporary.
The Valuation Debate Is Really About Other Cancers
Rothschild’s argument is not that intismeran failed in melanoma.
It is that Moderna’s stock may already be assigning substantial value to cancers where the treatment has not yet demonstrated the same success.
Moderna and Merck have been testing the individualized cancer therapy across several tumor types, including non-small cell lung cancer, bladder cancer and renal-cell carcinoma, alongside additional melanoma studies.
Success in even a few of those indications could dramatically expand the commercial opportunity.
Failure would leave melanoma carrying much more of the valuation.
That is why extrapolating one successful cancer trial across the entire oncology pipeline creates risk.
Melanoma is considered particularly responsive to immunotherapy and often contains large numbers of mutations that can provide targets for individualized treatments. Other tumors may behave differently.
A recent setback elsewhere in the mRNA cancer field reinforces that uncertainty.
BioNTech and Genentech halted a mid-stage study of their individualized mRNA cancer vaccine in colorectal cancer last month after an independent committee concluded the trial was unlikely to demonstrate an overall-survival benefit.
BioNTech’s candidate is different from Moderna’s, and failure of one program does not establish anything about intismeran’s prospects. It does show why success in melanoma cannot automatically be assumed to transfer to less immunologically responsive tumors.
Wall Street Is Sharply Divided
Rothschild is now only the second major Wall Street firm with a Sell-equivalent recommendation on Moderna, joining JPMorgan.
JPMorgan recently raised its price target to $77 while retaining an Underweight rating.
Other analysts have responded much more positively.
Argus upgraded Moderna to Buy with a $180 target following the cancer-vaccine breakthrough. UBS increased its target to $150, Goldman Sachs moved to $120 and Barclays raised its target to $125.
That unusually wide range illustrates how much disagreement now surrounds the company’s pipeline valuation.
The bull case is straightforward: Phase 3 melanoma success validates years of investment in Moderna’s underlying mRNA platform and could open an entirely new oncology franchise worth billions of dollars if the treatment works in multiple cancers.
The bearish case is that investors have already capitalized much of that possibility before seeing evidence from the additional tumor types required to support it.
At Thursday’s close, Moderna was worth roughly $59 billion despite generating only $145 million of revenue during its most recent quarter and remaining deeply unprofitable.
That does not automatically mean the stock is expensive. Biotechnology companies are often valued primarily on future products rather than current earnings.
But it does mean a large portion of Moderna’s valuation now depends on future clinical and commercial execution.
Moderna Is Still Burning Significant Cash
The company’s current financial results show why the oncology pipeline matters so much.
Second-quarter revenue reached $145 million, little changed from $142 million a year earlier. Lower COVID vaccine sales in the U.S. and South America were offset by U.K. deliveries and other revenue.
Moderna posted a $782 million net loss, or $1.97 per share, an improvement from a $2.13-per-share loss the previous year.
Research and development spending remained substantial at $651 million during the quarter, while selling, general and administrative expenses totaled $216 million.
The company ended June with $6.9 billion in cash, cash equivalents and investments, down from $7.5 billion at the end of March.
Moderna subsequently paid $950 million in July related to a patent-litigation settlement.
Management expects to finish 2026 with between $4.7 billion and $5.2 billion of cash and investments while targeting as much as 10% revenue growth for the year.
Moderna recently strengthened that financial position further by issuing $3 billion of zero-interest convertible senior notes due in 2032.
The offering was initially planned at $2 billion before being upsized. Moderna said proceeds could be used for general corporate purposes, including investment in the expansion of its oncology business and repayment of debt.
That financing gives Moderna additional flexibility to fund intismeran and other programs, though convertible debt can ultimately create dilution depending on the stock price and how the securities are settled.
The Company Is Becoming More Than a COVID Vaccine Story
There are signs Moderna’s commercial base is also broadening.
The FDA approved MFLUSIVA on August 5, giving Moderna its first seasonal influenza vaccine.
The vaccine is approved for adults 50 and older. Traditional approval covers adults ages 50 through 64, while use in adults 65 and older received accelerated approval subject to additional requirements to confirm clinical benefit.
Moderna also markets RSV and newer COVID vaccines.
Those products matter because they can reduce the company’s dependence on its original Spikevax franchise while oncology development continues.
The scale of the opportunity from intismeran, however, is considerably larger than the incremental contribution from another respiratory vaccine if the cancer therapy ultimately succeeds across multiple tumors.
That explains why the August melanoma announcement caused such an extreme repricing.
What Moderna Investors Should Watch Next
The full INTerpath-001 dataset is now the most immediate catalyst.
Investors will want to see the exact recurrence-free survival and metastasis data, results across patient subgroups, safety information and any additional evidence surrounding overall survival.
Regulatory timing comes next.
The successful Phase 3 study could support filings for approval in melanoma, and a U.S. launch could potentially begin as early as 2027 if regulators accept the data and the review proceeds successfully. That timeline remains an expectation rather than a confirmed approval schedule.
Beyond melanoma, trial results from lung, kidney, bladder and other cancers will determine whether Rothschild’s valuation warning proves justified.
Those readouts are where the stock’s long-term upside becomes much larger—or where expectations begin to narrow back toward melanoma alone.
Investors should also track Moderna’s cash burn. Even with billions of dollars in liquidity and the new convertible financing, developing individualized cancer therapies at global scale will require sustained research, manufacturing and commercialization spending.
Thursday’s downgrade does not challenge the scientific significance of Moderna’s August breakthrough. Rothschild itself acknowledged that the Phase 3 result was a major success.
The dispute is over price.
At roughly $149 a share after gaining 156% in August, Moderna is no longer valued as a struggling post-pandemic vaccine company waiting to prove that its technology has another major use.
The market has begun valuing it as a potential oncology platform.
The next clinical data will determine how much of that transformation is supported by evidence—and how much investors have already paid for before it arrives.